Grand Brilliance Group Holdings Limited (8372) AI Stock Analysis

Grand Brilliance Group Holdings Limited

(HKEX:8372)

Select Model

Rating:69Neutral

Price Target:HKD 0.17▲(4.22% Upside)

Action:downgraded

Date:12/09/25

The stock’s score is driven primarily by sound profitability and an exceptionally conservative balance sheet, partially offset by weak recent cash flow metrics, while a reasonable valuation and technically overbought price action keep the overall rating in the upper‑mid range rather than higher.

Positive Factors

Revenue GrowthThe company exhibits strong top-line expansion (reported ~27.9% revenue growth and a 14.78% increase in the latest year), indicating sustained demand and improved market penetration. Durable revenue momentum supports reinvestment, margin leverage and multi-quarter earnings stability.

Negative Factors

Free Cash Flow DeclineA steep 87% drop in free cash flow growth and very low operating cash flow to net income ratio (0.072) signal weak cash conversion of reported earnings. This durable cash generation shortfall can constrain capex, working capital flexibility and dividend/special distribution capacity over coming quarters.

Grand Brilliance Group Holdings Limited (8372) vs. iShares MSCI Hong Kong ETF (EWH)

Market Cap: HKD 132.80M
Dividend Yield: 1.51%
Average Volume (3M): 308.86K
Price to Earnings (P/E): 12.6
Beta (1Y): 0.20
Revenue Growth: 6.63%
EPS Growth: -11.02%
Country: Hong Kong
Employees: 51
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Distribution

Grand Brilliance Group Holdings Limited Business Overview & Revenue Model

Company Description

Grand Brilliance Group Holdings Limited, an investment holding entity, primarily operates by distributing medical equipment and related items across Hong Kong. Its extensive product portfolio encompasses various medical supplies, including disposable...

How the Company Makes Money

null

Grand Brilliance Group Holdings Limited Financial Statement Overview

Summary

Strong profitability and revenue growth plus a very conservative balance sheet are offset by sharply deteriorating cash generation and volatile free cash flow, leading to a solid but risk-qualified financial profile.

Income Statement

73Positive

Balance Sheet

84Very Positive

Cash Flow

45Neutral

Financial statement breakdown
Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	102.98M	100.71M	94.45M	81.90M	76.70M	71.98M
Gross Profit	46.60M	43.80M	45.72M	41.94M	39.51M	36.35M
EBITDA	10.31M	9.34M	13.95M	13.20M	14.09M	9.87M
Net Income	9.24M	8.41M	9.46M	7.86M	7.56M	4.05M
Balance Sheet
Total Assets	134.70M	134.70M	132.19M	114.50M	115.25M	110.32M
Cash, Cash Equivalents and Short-Term Investments	57.41M	54.19M	60.96M	60.47M	61.86M	55.74M
Total Debt	2.05M	2.05M	3.91M	1.43M	4.45M	4.48M
Total Liabilities	17.15M	17.15M	20.75M	11.22M	16.58M	16.82M
Stockholders Equity	117.20M	117.20M	110.79M	103.33M	98.67M	93.51M
Cash Flow
Free Cash Flow	-6.51M	0	1.17M	4.91M	12.60M	-4.12M
Operating Cash Flow	-5.34M	0	1.35M	6.72M	12.66M	-3.33M
Investing Cash Flow	2.50M	0	3.77M	-395.00K	-510.00K	-3.96M
Financing Cash Flow	-5.76M	0	-4.87M	-7.42M	-6.40M	-7.58M

Grand Brilliance Group Holdings Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price0.17

Price Trends

50DMA0.16Positive

100DMA0.15Positive

200DMA0.14Positive

Market Momentum

MACD0.00Positive

RSI62.35Neutral

STOCH68.00Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8372, the sentiment is Positive. The current price of 0.17 is below the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.16, and above the 200-day MA of 0.14, indicating a bullish trend. The MACD of 0.00 indicates Positive momentum. The RSI at 62.35 is Neutral, neither overbought nor oversold. The STOCH value of 68.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8372.

Grand Brilliance Group Holdings Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

HK:8372 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:2192	81Outperform	HKD 4.67B	11.63	7.05%	4.98%	6.47%	8.10%
HK:8372	69Neutral	HKD 132.80M	12.57	9.21%	1.51%	6.63%	-11.02%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:2289	47Neutral	HKD 592.92M	10.83	7.70%	6.26%	14.25%	0.83%
HK:0673	39Underperform	HKD 360.66M	-5.29	-273.18%	―	5.52%	56.54%
HK:1931	26Underperform	HKD 575.63M	-6.46	-2.60%	―	-2.55%	-145.60%

* Healthcare Sector Average

Performance Comparison

HK:8372 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
HK:8372	Grand Brilliance Group Holdings Limited	0.17	0.07	69.39%
HK:0673	China Health Group	0.26	-0.36	-58.06%
HK:1931	IVD Medical Holding Limited	0.35	-5.93	-94.35%
HK:2192	Medlive Technology Co., Ltd.	6.30	-4.03	-38.99%
HK:2289	Charmacy Pharmaceutical Co., Ltd. Class H	5.49	0.38	7.46%
HK:2427	Guanze Medical Information Industry (Holding) Co., Ltd.	2.30	1.80	360.00%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 09, 2025

Grand Brilliance Group Holdings Limited AI Stock Analysis